Deutetrabenazine in the treatment of tardive dyskinesia induced by antipsychotics: a case report
10.3760/cma.j.cn113661-20210520-00167
- VernacularTitle:氘丁苯那嗪治疗抗精神病药引起的迟发性运动障碍1例
- Author:
Li SUN
1
;
Lili CAI
1
;
Guangbiao HUANG
1
Author Information
1. 湖州市第三人民医院 湖州师范学院附属第三医院，湖州313000
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Movement disorders;
Antipsychotic agents;
Deutetrabenazine
- From:
Chinese Journal of Psychiatry
2022;55(2):142-144
- CountryChina
- Language:Chinese
-
Abstract:
Tardive dyskinesia (TD) is a common adverse reaction during the treatment of antipsychotic drugs and there is no satisfactory treatment for it. Deutetrabenazine has been approved by FDA in 2017 to treat TD. This drug has just been launched in China and there are few reports on its clinical application in China. This article reports a 19-year-old female diagnosed with "schizophrenia". She has taken antipsychotics for a long time. Recently, she had symptoms such as the opening mouth and sticking tongue out, head and neck receding, difficulty chewing, slurred speech, drooling, etc. and was diagnosed with "TD". She was adjusted for drugs and was prescribed vitamin E and clonazepam. The therapeutic effect of this symptomatic treatment was poor. After being treated with Deutetrabenazine, her symptoms gradually alleviated and the therapeutic effect was definite. This case report will provide references and experience for clinical work.
